SAISHO
SAISHO provides an AI-driven platform that predicts clinical success for drug candidates using only molecular structure, biological target, and intended indication—before extensive preclinical data exists. The service explains specific risks, separates fixable issues from stop-reasons, and delivers assessments aligned with a client's decision date to support go/no-go decisions.
- Drug Discovery & Therapeutics
- Artificial Intelligence
- Data & Analytics
- Biotechnology
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Drug development teams face enormous uncertainty when deciding which candidates to advance, often lacking reliable signals of clinical success before committing years and hundreds of millions of dollars to trials. Without a consistent, early-stage evaluation method, teams and investors must rely on incomplete evidence when making high-stakes go/no-go decisions about drug candidates.
Solution
SAISHO predicts clinical success from just a drug's chemical structure, its biological target, and the intended indication, delivering assessments before extensive preclinical and clinical data are available. The platform not only predicts whether a candidate will succeed in the clinic but also explains the specific risks associated with the asset, helping teams understand the basis for each prediction. It separates fixable problems from reasons to stop development, enabling drug teams and investors to act on clear, actionable intelligence. The service is structured around a simple workflow: bring an asset and a decision date, and SAISHO will deliver what the evidence supports for that candidate.
Target Audience
Primary users are drug development teams at biopharmaceutical companies and investors who commit substantial capital to drug candidates and need early, evidence-based clinical success predictions to inform their decisions.
Features
- Structure-based prediction engine that analyzes clinical success potential from molecular structure alone
- Target and indication analysis to contextualize predictions within the specific therapeutic context
- Risk explanation layer that identifies and communicates the factors driving each prediction
- Differentiation between fixable problems and stop-reasons to directly inform go/no-go decisions
- Decision-date oriented assessments that align with the actual timelines of development planning
- Consistent evaluation framework designed to give drug teams and investors a standardized basis for capital-intensive decisions